Pendulum Probiotics Review: Does the Akkermansia + Glucose Formula Work?

Pendulum is the rare consumer probiotic that did something most of its competitors never bother to do: it ran its own randomized controlled trial and published the result. That alone puts it in a different evidentiary tier from the average shelf probiotic, which leans on borrowed strain studies and mechanism stories. But "has a trial" and "has strong evidence" are not the same thing, and the gap between them is exactly where an honest review has to live. This page walks through what Pendulum's flagship product actually demonstrated, what it didn't, and how much weight a single small, company-run study can carry.

What Pendulum is and what's in it

Pendulum Therapeutics (formerly Whole Biome) sells a line of medical-food and supplement probiotics aimed squarely at metabolic health — most famously its glucose-control formula built around Akkermansia muciniphila, the mucin-degrading gut microbe that's chronically under-represented in people with type 2 diabetes and obesity. Pendulum was the first company to commercialize a live Akkermansia product for consumers, and it's the headline ingredient in their marketing.

The flagship metabolic formula isn't Akkermansia alone, though. The version tested in their pivotal trial — designated WBF-011 — is a five-strain blend delivered with the prebiotic fiber inulin: Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Bifidobacterium infantis, and Anaerobutyricum hallii ¹. The logic of that roster is coherent: several of those strains are butyrate producers, and butyrate is a short-chain fatty acid tied to gut-barrier integrity and insulin signaling. Anaerobutyricum hallii (formerly Eubacterium hallii) in particular has been studied as a next-generation metabolic microbe with early human insulin-sensitivity signals ², and Akkermansia has its own proof-of-concept human data ³. So the formula is built on real biology, not a random grab-bag.

The headline: Pendulum has its own A1c trial

Here's what genuinely sets Pendulum apart. In 2020 the company published a 12-week, multicenter, double-blind, randomized, placebo-controlled trial in BMJ Open Diabetes Research & Care — a peer-reviewed journal — testing its probiotic formulations in adults with type 2 diabetes ¹. Seventy-six participants were randomized to placebo, a three-strain formula (WBF-010), or the five-strain WBF-011 ¹.

The five-strain WBF-011 group hit the primary outcome: compared with placebo, it significantly improved post-meal glucose total area-under-the-curve by −36.1 mg/dL over 180 minutes (p=0.05) ¹. It also moved two secondary markers in the right direction — glycated hemoglobin (A1c) fell by 0.6 percentage points, and incremental glucose AUC dropped by 28.6 mg/dL/180 min ¹. No safety or tolerability problems showed up ¹. An A1c reduction of 0.6 is not trivial; it's in the neighborhood of what some add-on diabetes interventions deliver. If you only read the topline, this looks like a strong result.

So the first honest verdict is positive and specific: Pendulum's flagship formula has direct, peer-reviewed, randomized human evidence for improving postprandial glucose control — a claim almost no other consumer probiotic can make.

The caveats that the marketing leaves out

Now the part that matters just as much. A single trial — especially this one — has real limits, and the study's own authors say so plainly.

It's small. Seventy-six people split across three arms means roughly 25 per group ¹. With that sample size, a p-value sitting exactly at 0.05 on the primary endpoint is a fragile result — statistically "positive" by the thinnest possible margin. The authors explicitly call it a proof-of-concept study and write that "the limited sample size and intersubject variability justifies future studies designed to confirm and expand on these observations" ¹. That is the researchers themselves telling you not to treat this as settled.

It's short. Twelve weeks tells you about a three-month glucose response, not about durability, and certainly not about long-term outcomes like cardiovascular events or sustained A1c control over years.

It's single-sponsor. Every author on the trial is an employee and stock or stock-option holder of Pendulum Therapeutics ¹. That doesn't make the data fraudulent — it was published in a legitimate peer-reviewed journal with a registered protocol (NCT03893422) — but it does mean the only randomized evidence for this specific product comes from the company that sells it, with no independent replication. The gold standard the broader field holds probiotics to is exactly this kind of independent, repeated confirmation, and Pendulum doesn't yet have it.

"Boosts your metabolism" is doing a lot of work

Pendulum's products are marketed around metabolic health broadly — "metabolism," energy, weight. It's worth being precise about what the trial actually measured, because the gap is wide.

The WBF-011 trial measured glucose control in people with type 2 diabetes ¹. It did not measure weight loss, fat loss, energy, or "metabolic rate," and it wasn't conducted in metabolically healthy people. So the well-supported claim is narrow: in adults with T2D, this specific formula modestly improved post-meal glucose and A1c over 12 weeks. The broader "boost your metabolism" framing — the implication that a healthy person will burn more, weigh less, or feel more energetic — is not what the study tested, and there's no trial establishing it. We pull apart that same overreach for the underlying microbe in our Akkermansia evidence review and explain how gut bacteria plausibly touch glucose handling in the microbiome and insulin resistance.

The supporting science for the ingredients is real but mostly mechanistic or surrogate-level. Akkermansia's human proof-of-concept trial in overweight/obese volunteers improved insulin sensitivity and some metabolic markers, but it was itself a small pilot ³ — and intriguingly, the benefit in that line of research often tracks with a pasteurized (non-live) form and a specific membrane protein, not necessarily the live organism Pendulum sells ⁴⁵. That nuance matters enough that we devote a whole piece to it: live vs pasteurized Akkermansia. The point isn't that the science is bad — it's that the ingredient evidence and the finished-product evidence are different things, and only the WBF-011 trial speaks to the actual product.

How it fits the broader probiotic-for-glucose picture

Zoom out, and Pendulum's result is consistent with — but at the stronger end of — what the wider literature shows. A GRADE-assessed meta-analysis of probiotics and synbiotics in prediabetes and type 2 diabetes found modest but real improvements in glycemic parameters across many trials ⁶. Pendulum's formula is one entry in that body of work, distinguished mainly by being a defined, branded, multi-strain product with its own registered RCT rather than a generic strain riding on category-level meta-analyses. That's a meaningful edge on transparency. It is not, by itself, proof of superiority over other approaches, because no head-to-head trial exists.

It's also worth remembering the strict standard the field uses: a probiotic benefit has to be demonstrated for the specific formulation and dose, not assumed from the genus ⁷. Pendulum actually meets that bar for its glucose claim — which is the whole reason it earns a better grade than most. The honest caveat is just that it meets it with one small, short, sponsor-run study.

Who it might suit — and who should talk to a doctor first

If you have type 2 diabetes or prediabetes and you want a probiotic with direct (not borrowed) human evidence behind a glucose claim, Pendulum is one of the few products that can honestly offer that — with the caveats above kept firmly in view. It is an adjunct to dietary management, not a replacement for prescribed medication, and the trial framed it exactly that way ¹. Anyone on glucose-lowering drugs should loop in their clinician before adding it, both because of the modest additive glucose effect and because Akkermansia-containing live products warrant the usual caution in immunocompromised or critically ill people.

For where it sits against the wider field of glucose-targeting probiotics, see our best probiotics for blood sugar review and our ranked best metabolic probiotic guide; for the system-level "why" behind all of it, start with the gut–metabolism connection.

The bottom line

Pendulum earns real credit for doing what almost no consumer probiotic does — running and publishing its own randomized, placebo-controlled, peer-reviewed trial — and that trial showed a genuine, if modest, improvement in post-meal glucose and a 0.6-point A1c drop in people with type 2 diabetes ¹. That's the strongest direct evidence in the consumer probiotic aisle for a glucose claim. But it rests on a single, small (n=76), 12-week, proof-of-concept study run entirely by the company that sells the product, with a primary endpoint that just barely cleared significance and no independent replication ¹. The defensible read: Pendulum is a legitimately evidence-backed glucose-support probiotic for people with T2D — better-supported than most — but the "metabolism-boosting" halo around it runs well ahead of what one small sponsor trial can prove.